Theory and strategy for Pneumococcal vaccines in the elderly

Ho Namkoong, Makoto Ishii, Yohei Funatsu, Yoshifumi Kimizuka, Kazuma Yagi, Takahiro Asami, Takanori Asakura, Shoji Suzuki, Testuro Kamo, Hiroshi Fujiwara, Sadatomo Tasaka, Tomoko Betsuyaku, Naoki Hasegawa

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Pneumonia is the fourth-leading cause of death globally, and Streptococcus pneumoniae is the most important causative pathogen. Because the incidence of pneumococcal diseases is likely to increase with the aging society, we should determine an optimal strategy for pneumococcal vaccination. While consensus indicates that 23-valent pneumococcal polysaccharide vaccine prevents invasive pneumococcal diseases (IPD), its effects on community-acquired pneumonia (CAP) remain controversial. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) was released. The latest clinical study (CAPiTA study) showed that PCV13 reduced vaccine-type CAP and IPD. Based on these results, the Advisory Committee on Immunization Practices recommended initial vaccination with PCV13 for the elderly. Scientific evidence regarding immunosenescence is needed to determine a more ideal vaccination strategy for the elderly with impaired innate and adaptive immunity. Continuing research on the cost effectiveness of new vaccine strategies considering constantly changing epidemiology is also warranted.

Original languageEnglish
Pages (from-to)336-343
Number of pages8
JournalHuman Vaccines and Immunotherapeutics
Issue number2
Publication statusPublished - 2016 Feb 1


  • aging
  • elderly
  • pneumococcal conjugate vaccine
  • pneumococcal diseases
  • pneumococcal polysaccharide vaccine
  • pneumococcal vaccines
  • senescence

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Theory and strategy for Pneumococcal vaccines in the elderly'. Together they form a unique fingerprint.

Cite this